In the metastatic breast cancer sphere, 2 chemotherapy agents have come to the forefront: capecitabine, for metastatic breast cancer, and eribulin, for triple-negative breast cancer (TNBC). Each agent has shown improvement in overall survival rates compared with standard chemotherapy for heavily pretreated patients with metastatic disease. Recent phase 3 trials have explored the potential of these agents in TNBC in particular. Ahead, John Crown, MD, MBA, professor and consultant of medical oncology at St. Vincent’s Private Hospital in Dublin, Ireland, discusses these and other strides made on the evolving TNBC treatment front.
OncLive®: What is chemotherapy’s current role in the triple-negative space?
Crown: One thing we’ve learned in recent years is [that] the old blanket designation of TNBC as chemotherapy-insensitive cancer is not correct. At this point in time, despite the…
